Previous 10 | Next 10 |
NeuroBo to Participate in Industry and Investor Conferences in January PR Newswire CAMBRIDGE, Mass. , Jan. 2, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic dis...
NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity PR Newswire CAMBRIDGE, Mass. , Dec. 28, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotech...
2023-12-19 10:05:25 ET More on NeuroBo Pharmaceuticals Seeking Alpha’s Quant Rating on NeuroBo Pharmaceuticals Historical earnings data for NeuroBo Pharmaceuticals Financial information for NeuroBo Pharmaceuticals For further details see: NeuroBo P...
NeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock Split PR Newswire Commencement of Trading on Split-Adjusted Basis on December 21, 2023 BOSTON , Dec. 19, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage bi...
NEW YORK, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Investor Forum sponsored by Zacks Small-Cap Research. held December 14 th are now available for online viewing....
NEW YORK, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Science Investor Forum to be held December 14 th . This event is sponsored by Zacks Small-Cap Research. Individual investors, i...
NeuroBo to Participate in Investor Conferences in December PR Newswire BOSTON , Dec. 1, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on the transformation of cardiometabolic disease...
2023-11-13 17:30:15 ET More on NeuroBo Pharmaceuticals Seeking Alpha’s Quant Rating on NeuroBo Pharmaceuticals Historical earnings data for NeuroBo Pharmaceuticals Financial information for NeuroBo Pharmaceuticals For further details see: NeuroBo P...
NeuroBo Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update PR Newswire DA-1726 Phase 1 IND Filing Expected by Year End 2023 Board Strengthened with Recent Appointment of Industry Veteran, James P. Tursi , M.D. Cash an...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
News, Short Squeeze, Breakout and More Instantly...
NeuroBo Pharmaceuticals Inc. Company Name:
NRBO Stock Symbol:
NASDAQ Market:
NeuroBo Pharmaceuticals Inc. Website:
NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity PR Newswire Top-Line Data Readout From the Single Ascending Dose Part 1 Expected in the Third Quarter of 2024, and From the Multiple Asce...
NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules PR Newswire $20 million upfront with up to an additional $50 million of aggregate gross proceeds upon ...
NeuroBo Pharmaceuticals Announces up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules PR Newswire $20 million upfront with up to an additional $50 million of aggregate gross proceeds upon the exercise in...